Squamous cell carcinoma of the head and neck (SCCHN) is the most common type of head and neck cancer. About half of the people with locally advanced (LA) SCCHN will have surgery to remove their cancer. For people who do not have surgery, chemoradiotherapy is the standard treatment, with the aim of fully removing the cancer. However, in many people, this treatment does not completely kill the cancer. This summary presents the main results of a phase 2 study of a medicine called xevinapant, which is under investigation as a potential future medicine for people with this type of cancerThis is a Plain Language Summary of Publication article published in Future Oncology. Squamous cell carcinoma of the head and neck (SCCHN) is the most common type of head and neck cancer. For people with SCCHN who don’t have surgery to remove the cancer, chemoradiotherapy is the standard therapy, however, this treatment often doesn’t kill the cancer completely. This article looks at a medicine called xevinapant as a potential future medicine for people with SCCHN.

You can read the full Plain Language Summary here.

This summary is based on the original article called ‘Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial’ which was published in the European Journal Of Cancer. 

Read the original article here.